Moderna (MRNA) Liabilities and Shareholders Equity (2017 - 2026)

Moderna has reported Liabilities and Shareholders Equity for 10 years, with the latest figure at $11.0 billion in Q2 2026.

• Liabilities and Shareholders Equity for Q2 2026 came in at $11.0 billion, down 8.73% year-over-year; the trailing twelve-month figure through Jun 2026 was $46.9 billion (down 14.16% YoY), and the FY2025 annual result was $12.3 billion, down 12.76% from the prior year.
• Liabilities and Shareholders Equity eased to $11.0 billion in Q2 2026, from $11.5 billion in the prior quarter.
• Over five years, Liabilities and Shareholders Equity peaked at $27.6 billion in Q1 2022 and troughed at $11.0 billion in Q2 2026.
• A 5-year average of $18.0 billion and a median of $16.3 billion in 2024 frame the typical range for Liabilities and Shareholders Equity.
• The widest annual swing landed in 2022, when Liabilities and Shareholders Equity soared 117.5%; it then slumped 30.66% in 2024.
• A 5-year view of Liabilities and Shareholders Equity shows it stood at $25.9 billion in 2022, then slipped by 28.74% to $18.4 billion in 2023, then retreated by 23.25% to $14.1 billion in 2024, then slipped by 12.76% to $12.3 billion in 2025, then fell by 11.16% to $11.0 billion in 2026.
• Per Business Quant data, the three most recent Liabilities and Shareholders Equity figures were $11.0 billion in Q2 2026, $11.5 billion in Q1 2026, and $12.3 billion in Q4 2025.